Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients

Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell... Adoptive cell therapy (ACT) of tumor infiltration lymphocytes (TIL) yields promising clinical results in metastatic melanoma patients, who failed standard treatments. Due to the fact that metastatic lung cancer has proven to be susceptible to immunotherapy and possesses a high mutation burden, which makes it responsive to T cell attack, we explored the feasibility of TIL ACT in non-small cell lung cancer (NSCLC) patients. Multiple TIL cultures were isolated from tumor specimens of five NSCLC patients undergoing thoracic surgery. We were able to successfully establish TIL cultures by various methods from all patients within an average of 14 days. Fifteen lung TIL cultures were further expanded to treatment levels under good manufacturing practice conditions and functionally and phenotypically characterized. Lung TIL expanded equally well as 103 melanoma TIL obtained from melanoma patients previously treated at our center, and had a similar phenotype regarding PD1, CD28, and 4-1BB expressions, but contained a higher percent of CD4 T cells. Lung carcinoma cell lines were established from three patients of which two possessed TIL cultures with specific in vitro anti-tumor reactivity. Here, we report the successful pre-clinical production of TIL for immunotherapy in the lung cancer setting, which may provide a new treatment modality for patients with metastatic NSCLC. The initiation of a clinical trial is planned for the near future. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Immunology, Immunotherapy Springer Journals

Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients

Download PDF
10 pages

Loading next page...
 
/lp/springer_journal/establishment-of-adoptive-cell-therapy-with-tumor-infiltrating-bKXcD0ErXc
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Immunology; Cancer Research
ISSN
0340-7004
eISSN
1432-0851
DOI
10.1007/s00262-018-2174-4
pmid
29845338
Publisher site
See Article on Publisher Site

Abstract

Adoptive cell therapy (ACT) of tumor infiltration lymphocytes (TIL) yields promising clinical results in metastatic melanoma patients, who failed standard treatments. Due to the fact that metastatic lung cancer has proven to be susceptible to immunotherapy and possesses a high mutation burden, which makes it responsive to T cell attack, we explored the feasibility of TIL ACT in non-small cell lung cancer (NSCLC) patients. Multiple TIL cultures were isolated from tumor specimens of five NSCLC patients undergoing thoracic surgery. We were able to successfully establish TIL cultures by various methods from all patients within an average of 14 days. Fifteen lung TIL cultures were further expanded to treatment levels under good manufacturing practice conditions and functionally and phenotypically characterized. Lung TIL expanded equally well as 103 melanoma TIL obtained from melanoma patients previously treated at our center, and had a similar phenotype regarding PD1, CD28, and 4-1BB expressions, but contained a higher percent of CD4 T cells. Lung carcinoma cell lines were established from three patients of which two possessed TIL cultures with specific in vitro anti-tumor reactivity. Here, we report the successful pre-clinical production of TIL for immunotherapy in the lung cancer setting, which may provide a new treatment modality for patients with metastatic NSCLC. The initiation of a clinical trial is planned for the near future.

Journal

Cancer Immunology, Immunotherapy – Springer Journals

Published: May 29, 2018

References

  • Cancer statistics, 2016
    Siegel, RL; Miller, KD; Jemal, A
  • New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Doebele, RC; Oton, AB; Peled, N; Camidge, DR; Bunn, PA
  • Immunotherapy: beyond anti-PD-1 and anti-PD-L1 therapies
    Antonia, SJ; Vansteenkiste, JF; Moon, E
  • Clinical trials investigating immune checkpoint inhibitors in non-small-cell lung cancer
    Giri, A; Walia, SS; Gajra, A
  • Immunotherapy for non-small cell lung cancer: current concepts and clinical trials
    Mayor, M; Yang, N; Sterman, D; Jones, DR; Adusumilli, PS
  • The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next?
    Shin, DS; Ribas, A
  • Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer
    Horne, ZD; Jack, R; Gray, ZT
  • Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors
    Kilic, A; Landreneau, RJ; Luketich, JD; Pennathur, A; Schuchert, MJ
  • Mutational heterogeneity in cancer and the search for new cancer-associated genes
    Lawrence, MS; Stojanov, P; Polak, P
  • Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions
    Lu, YC; Yao, X; Crystal, JS
  • Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
    Robbins, PF; Lu, YC; El-Gamil, M
  • Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Dudley, ME; Wunderlich, JR; Yang, JC
  • Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy
    Itzhaki, O; Hovav, E; Ziporen, Y
  • Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen
    Andersen, R; Donia, M; Ellebaek, E
  • Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies
    Besser, MJ; Shapira-Frommer, R; Itzhaki, O
  • Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma
    Dudley, ME; Gross, CA; Somerville, RP
  • Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma
    Goff, SL; Dudley, ME; Citrin, DE
  • Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma
    Pilon-Thomas, S; Kuhn, L; Ellwanger, S
  • Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients
    Radvanyi, LG; Bernatchez, C; Zhang, M
  • A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma
    Ratto, GB; Zino, P; Mirabelli, S
  • Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment
    Jin, J; Sabatino, M; Somerville, R; Wilson, JR; Dudley, ME; Stroncek, DF; Rosenberg, SA
  • Selection of shared and neoantigen reactive T cells for adoptive cell therapy based on CD137 separation
    Seliktar-Ofir, S; Merhavi-Shoham, E; Itzhaki, O
  • Reassessing target antigens for adoptive T-cell therapy
    Hinrichs, CS; Restifo, NP